Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial

Susceptibility ofKlebsiella pneumoniaeIsolates from Intra-Abdominal Infections and Molecular Characterization of Ertapenem-Resistant Isolates

(2011) Stephen P. Hawser et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)

(2011) A. Walkty et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases

(2011) P. R. S. Lagacé-Wiens et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa

(2011) Souha S. Kanj et al.   MAYO CLINIC PROCEEDINGS

Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae

(2010) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Incidence and Antimicrobial Susceptibility of Escherichia coli and Klebsiella pneumoniae with Extended-Spectrum  -Lactamases in Community- and Hospital-Associated Intra-Abdominal Infections in Europe: Results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART)

(2010) S. P. Hawser et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Susceptibility of Gram-Negative Pathogens Isolated from Patients with Complicated Intra-Abdominal Infections in the United States, 2007-2008: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART)

(2010) D. J. Hoban et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-ProducingKlebsiella pneumoniae

(2010) Andrea Endimiani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia–Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)

(2010) Po-Ren Hsueh et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Antibiotic susceptibility of intra-abdominal infection isolates from Indian hospitals during 2008

(2010) Stephen P. Hawser et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Epidemiologic Trends, Occurrence of Extended-Spectrum β-Lactamase Production, and Performance of Ertapenem and Comparators in Patients with Intra-Abdominal Infections: Analysis of Global Trend Data from 2002–2007 from the SMART Study

(2010) Stephen P. Hawser et al.   Surgical Infections

In Vitro Activity of NXL104 in Combination with  -Lactams against Klebsiella pneumoniae Isolates Producing KPC Carbapenemases

(2009) A. Endimiani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diagnosis and Management of Complicated Intra‐abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America

(2009) Joseph S. Solomkin et al.   CLINICAL INFECTIOUS DISEASES

In vitro activity of the  -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases

(2009) T. Stachyra et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria

(2009) Patrice Nordmann et al.   LANCET INFECTIOUS DISEASES

Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study

(2008) Christopher Lucasti et al.   CLINICAL THERAPEUTICS

NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum  -lactamases and carbapenemases

(2008) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY